Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology

NovartisToday Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbourne, Australia on Aug 22, 2016. The Novartis Prizes for Immunology are awarded every three years for breakthrough contributions to the fields of basic and clinical immunology. Each of the two Prize categories is endowed for CHF 100,000 and can be shared by up to three scientists.

"This year's prize recipients are scientific pioneers who have delivered novel concepts and opened the door to uncharted fields at the forefront of immunological research," said Dhavalkumar D. Patel, M.D., Ph.D, Head of Research Europe and Global Head, Autoimmunity, Transplantation and Inflammation research at the Novartis Institutes for BioMedical Research. "We are proud to sponsor these prizes as part of our continued commitment to supporting innovative research in immunology."

The winners were selected by an independent jury of seven world-class immunologists for their groundbreaking research into the biology of the immune system. Each recipient has had a tremendous impact on the understanding of T-cell mediated mechanisms such as tolerance (basic immunology) and how these principles can be exploited to design therapeutic approaches (clinical immunology).

The Novartis Prize for Basic Immunology 2016 is shared by John Kappler (National Jewish Health, USA), Philippa Marrack (National Jewish Health, USA) and Harald von Boehmer (Emeritus, Harvard Medical School, USA) for their work in demonstrating how the immune system is able to discriminate "self" from "non-self" through a process in the thymus based on positive and negative selection via T-cell receptor mediated recognition of peptide-MHC complexes.

The Novartis Prize for Clinical Immunology 2016 is awarded to Zelig Eshhar (Weizmann Institute of Science, Israel), Carl June (University of Pennsylvania, USA) and Steven Rosenberg (National Institutes of Health, USA) for their work on the pre-clinical and clinical development as well as technological application of cellular immune therapy using Chimeric Antigen Receptor-T cells (CAR-T-cells) for diseases such as cancer.

"Immune disorders destroy the lives of many and increased research in this field is vital," said Hidde Ploegh, Jury chair, "these prestigious awards recognize the outstanding contributions made by the world's top scientists. It is so important that we recognize and reward these exceptional scientists who have paved the way for future research and treatment."

For more information on the prizes go to: http://www.novartisimmunologyprizes.com

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Researchers develop a new method for turning skin …

Our bodies consist of many different kinds of cells, each with their own role. The Japanese scientist Shinya Yamanaka had made earlier the discovery, earning the Nobel Pr...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...

Human clinical trial reveals verapamil as an effec…

Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

New small molecules pave the way for treating auto…

The innate immune system is the first line of defense, with cells that quickly identify "foreign" motifs from viruses and bacteria and mount up a counterattack to elimina...

How targeting metabolism can defeat cancer stem ce…

Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment. In a breakthroug...

Amgen and MBC Biolabs announce winners of the Amge…

Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company recei...

FDA warns of imposters sending consumers fake warn…

The U.S. Food and Drug Administration is warning consumers about criminals forging FDA warning letters to target individuals who tried to purchase medicines online or ove...